Volume 4 (Issue 1, 2, 3) 2019
Share on whatsapp
Share on twitter
Share on facebook

Autism Spectrum Disorder: Medications overview

Aslam Pathan , Feras Almarshad

2019, Volume 4, Issue 1, January-April [Download full PDF]


FDA-approves the first therapy in 2018 for the seizures associated with Dravet syndrome

Aslam Pathan ,Abdulrahman Alshahrani

2019, Volume 4, Issue 1, January-April [Download full PDF]


Cannabidiol: FDA approved new drug for the LennoxGastaut syndrome and Dravet syndrome: Pharmacotherapeutics review

Aslam Pathan, PhD, MANF

2019, Volume 4, Issue 1, January-April [Download full PDF]


Caplacizumab: First FDAapproved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura

Feras Almarshad

2019, Volume 4, Issue 1, January-April [Download full PDF]


Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review

Aslam Pathan, PhD, MANF

2019, Volume 4, Issue 1, January-April [Download full PDF]


Siponimod: A new approved oral drug to treat multiple sclerosis

Aslam Pathan, PhD, MANF

May-August 2019 Volume 4, Issue 2 [Download full PDF]


Istradefylline: A new add-on drug to treat off episodes in adults with Parkinson’s disease

Aslam Pathan, PhD, MANF

May-August 2019 Volume 4, Issue 2 [Download full PDF]


FDA recalled Ranitidine: What about the consumers who ate Ranitidine with carcinogenic impurity by paying to Pharma companies?

Aslam Pathan, PhD, MANF

Sept-Dec 2019 Volume 4, Issue 3 [Download full PDF]


Top Pharma companies not following current good manufacturing processes: Angiotensin II receptor blockers with carcinogenic impurities: A threat to global public health

Aslam Pathan, PhD, MANF

Sept-Dec 2019 Volume 4, Issue 3 [Download full PDF]